Full Year 2023 Investor Presentation

40 Investor presentation Full year 2023 Novo NordiskⓇ Better outcomes and broader reach can be accomplished through continued innovation, supported by digital solutions Digital health solutions Portfolio and pipeline Novo Nordisk's product portfolio follows the patient treatment journey OZEMPIC TRESIBA Xultophy RYZODEG semaglutide injection insulin degludec [rDNA origin] injection Ozempic 2.0 mg RYBELSUSⓇ semaglutide tablets High dose oral semaglutide Uncontrolled on current OAD Needing first injectable Novo PenⓇ6 / Novo Pen Echo® Plus are smart insulin pens and launched in 28 countries Icodec IcoSema Needing first basal insulin Needing more than basal insulin 6.2 Abbott Medtronic 600 Roche mySugr glooko Dexcom® Fiasp fast-acting insulin aspart Needing added meal- time insulin control Partnered with global CGM players CGM: Continuous glucose monitoring; Grey boxes in the portfolio and pipeline references phase 2 or phase 3 assets.

View entire presentation